{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-011222","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.537834+00:00","generated_at":"2026-05-15T09:51:20.310840+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Hepion Pharma CEO Kaouthar Lbiati resigns; Gary Stetz named interim CEO","bullets":["CEO Dr. Kaouthar Lbiati resigned effective March 16, 2026, for personal reasons.","Board appointed Gary Stetz as interim CEO and director; Vincent LoPriore as Executive Chairman.","Sireesh Appajosyula and Chase LoPriore also appointed to the board of directors.","No family relationships or arrangements between new appointees and other officers disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-011222","json":"https://secwatch.observer/filing/0001493152-26-011222.json","markdown":"https://secwatch.observer/filing/0001493152-26-011222.md","text":"https://secwatch.observer/filing/0001493152-26-011222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226011222/0001493152-26-011222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226011222/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:51:20.310840+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}